Boston Scientific Corporation (BSX) — Fair Value Analysis
Base-case fair value (P50): $49.47 · Current price: $45.14 · Verdict: Fairly Valued
The Verdict on BSX
Based on our comprehensive Monte Carlo simulations, Boston Scientific (BSX) is currently deemed Fairly Valued. The analysis indicates that BSX's current price of $45.14 closely aligns with its median fair value (P50) of $49.47. This narrow band suggests that the market price largely reflects the company's intrinsic worth, resulting in an +9.6% against the current valuation. The proximity of $45.14 to $49.47 underlines the verdict that BSX offers limited immediate valuation arbitrage opportunities based on our model.
How BSX stacks up against Healthcare
Within the Healthcare sector, Boston Scientific maintains an "average" quality tier, reflecting its operational and financial health relative to its industry peers. This average quality profile is a key input into our Monte Carlo simulation, influencing the range and probability distribution of its fair value. While the $45.14 is in line with the $49.47 median, the "average" quality tier suggests that BSX possesses a balanced risk-reward profile, not exhibiting significant outperformance or underperformance in core fundamentals that would drastically skew its fair value. This positioning contributes to the stability seen in the +9.6% figure.
What this means for investors
For investors, the "Fairly Valued" verdict for BSX, with its current price of $45.14 closely matching the $49.47 fair value, implies that the stock may not offer substantial near-term upside driven by undervaluation. The +9.6% figure reinforces this perspective, suggesting little immediate dislocation between market price and intrinsic value according to our Monte Carlo model. To gain deeper insights into potential downside or upside scenarios for BSX, and to see the full probabilistic distribution generated by FairCurve's advanced analytics, investors should consider signing up for a free account to track BSX's fair value as new fundamentals are released.
Frequently Asked Questions
Is BSX overvalued or undervalued right now?
BSX is currently considered fairly valued. Our Monte Carlo simulations show its median fair value (P50) at $49.47, which is closely aligned with its current price of $45.14.
What is the bear case and bull case for BSX?
Our comprehensive Monte Carlo simulations generate a full distribution of potential fair values for BSX. The specific bear-case (P10) and bull-case (P90) price targets, alongside the probability of achieving upside, are exclusive features available to users with a free FairCurve account.
How does FairCurve calculate BSX's fair value?
FairCurve calculates BSX's fair value by employing advanced Monte Carlo simulations, running thousands of forward-looking scenarios to determine a probabilistic range of intrinsic values.
How can I track BSX's fair value as it changes?
You can track BSX's fair value daily by adding it to your free FairCurve watchlist. This ensures you receive instant re-valuations whenever new earnings or significant fundamental data are released.